Scholar Rock Holding Corporation Common Stock
SRRKScholar Rock Holding Corporation (SRRK) is a biopharmaceutical company focused on discovering and developing medicines that target growth factors involved in serious medical conditions. Its approach emphasizes precision medicine aimed at diseases such as fibrosis and cancer, utilizing its proprietary drug discovery platform to develop first-in-class therapeutics.
Company News
Scholar Rock's Chief Scientific Officer Mo Qatanani sold 14,898 shares on January 22, 2026, for approximately $695,938 as part of a pre-planned Rule 10b5-1 trading plan. The sale reduced his direct ownership to 85,660 shares (0.08% of outstanding shares). The company plans to launch its key product candidate apitegromab in U.S. and European marke...
Commodore Capital fully exited its position in Scholar Rock, selling approximately 1.5 million shares in Q3, representing a $51 million transaction. The biotech company is preparing to resubmit its apitegromab biologics license application after a previous FDA rejection.
The FDA approved Novartis' Itvisma, a gene replacement therapy for spinal muscular atrophy (SMA), which can treat patients two years and older by addressing the genetic root cause of the disease with a one-time fixed dose.
Scholar Rock's stock dropped over 13% after the FDA designated a Catalent Indiana manufacturing facility as Official Action Indicated (OAI), following a previous FDA rejection of its spinal muscular atrophy drug application.
Bank of America analyst Tazeen Ahmad initiated coverage on Scholar Rock, setting a buy rating with a $53 price target, which drove the stock up 6%. The analyst is particularly interested in the company's investigational spinal muscular atrophy (SMA) drug apitegromab.
